Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy.

Brandwein JM, Seki JT, Atenafu EG, Rostom A, Lutynski A, Rydlewski A, Schimmer AD, Schuh AC, Gupta V, Yee KWL.

Support Care Cancer. 2019 Jun;27(6):2295-2300. doi: 10.1007/s00520-018-4515-4. Epub 2018 Oct 19.

PMID:
30341536
2.

Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS.

Leitch HA, Buckstein R, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating MM, St Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Shamy A, Elemary M, Wells RA.

Leuk Res. 2018 Nov;74:21-41. doi: 10.1016/j.leukres.2018.09.005. Epub 2018 Sep 19. Review.

PMID:
30286330
3.

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.

Roboz GJ, Kantarjian HM, Yee KWL, Kropf PL, O'Connell CL, Griffiths EA, Stock W, Daver NG, Jabbour E, Ritchie EK, Walsh KJ, Rizzieri D, Lunin SD, Curio T, Chung W, Hao Y, Lowder JN, Azab M, Issa JJ.

Cancer. 2018 Jan 15;124(2):325-334. doi: 10.1002/cncr.31138. Epub 2017 Dec 6.

4.

Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.

Murphy T, Yee KWL.

Expert Opin Pharmacother. 2017 Nov;18(16):1765-1780. doi: 10.1080/14656566.2017.1391216. Epub 2017 Oct 20. Review.

PMID:
29017371
5.

A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.

Houston BL, Jayakar J, Wells RA, Lenis M, Zhang L, Zhu N, Leitch HA, Nevill TJ, Yee KWL, Leber B, Sabloff M, St-Hilaire E, Kumar R, Geddes M, Shamy A, Storring JM, Keating MM, Elemary M, Delage R, Mamedov A, Buckstein R.

Ann Hematol. 2017 Dec;96(12):2025-2029. doi: 10.1007/s00277-017-3137-0. Epub 2017 Oct 3.

PMID:
28975386
6.

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.

Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ.

Lancet Oncol. 2017 Oct;18(10):1317-1326. doi: 10.1016/S1470-2045(17)30576-4. Epub 2017 Aug 24.

7.

Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study.

Bartoszko J, Panzarella T, McNamara CJ, Lau A, Schimmer AD, Schuh AC, Sibai H, Maze D, Yee KWL, Devlin R, Gupta V.

Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):774-781. doi: 10.1016/j.clml.2017.06.031. Epub 2017 Jun 29.

PMID:
28711573
8.

Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.

Leitch HA, Parmar A, Wells RA, Chodirker L, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating MM, Sabloff M, St Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Kew A, Shamy A, Elemary M, Lenis M, Mamedov A, Ivo J, Francis J, Zhang L, Buckstein R.

Br J Haematol. 2017 Oct;179(1):83-97. doi: 10.1111/bjh.14825. Epub 2017 Jul 5.

PMID:
28677895
9.

ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.

Buckstein R, Balleari E, Wells R, Santini V, Sanna A, Salvetti C, Crisà E, Allione B, Danise P, Finelli C, Clavio M, Poloni A, Salvi F, Cilloni D, Oliva EN, Musto P, Houston B, Zhu N, Geddes M, Leitch H, Leber B, Sabloff M, Nevill TJ, Yee KW, Storring JM, Francis J, Maurillo L, Latagliata R, Spiriti MAA, Andriani A, Piccioni AL, Fianchi L, Fenu S, Gumenyuk S, Buccisano F.

Am J Hematol. 2017 Oct;92(10):1037-1046. doi: 10.1002/ajh.24842. Epub 2017 Jul 29.

10.

Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived.

Farshchi Zarabi S, Chan S, Gupta V, Khalaf D, Lutynski A, Minden MD, Rostom A, Rydlewski A, Schuh AC, Sibai H, Yee KWL, Schimmer AD.

Leuk Lymphoma. 2018 Jan;59(1):237-240. doi: 10.1080/10428194.2017.1323273. Epub 2017 Jun 9. No abstract available.

PMID:
28595467
11.

Synchronous cardiocerebral infarction in the era of endovascular therapy: which to treat first?

Yeo LLL, Andersson T, Yee KW, Tan BYQ, Paliwal P, Gopinathan A, Nadarajah M, Ting E, Teoh HL, Cherian R, Lundström E, Tay ELW, Sharma VK.

J Thromb Thrombolysis. 2017 Jul;44(1):104-111. doi: 10.1007/s11239-017-1484-2. Review.

PMID:
28220330
12.

A 17-gene stemness score for rapid determination of risk in acute leukaemia.

Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, Arruda A, Popescu A, Gupta V, Schimmer AD, Schuh AC, Yee KW, Bullinger L, Herold T, Görlich D, Büchner T, Hiddemann W, Berdel WE, Wörmann B, Cheok M, Preudhomme C, Dombret H, Metzeler K, Buske C, Löwenberg B, Valk PJ, Zandstra PW, Minden MD, Dick JE, Wang JC.

Nature. 2016 Dec 15;540(7633):433-437. doi: 10.1038/nature20598. Epub 2016 Dec 7.

PMID:
27926740
13.

A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia.

Reed GA, Schiller GJ, Kambhampati S, Tallman MS, Douer D, Minden MD, Yee KW, Gupta V, Brandwein J, Jitkova Y, Gronda M, Hurren R, Shamas-Din A, Schuh AC, Schimmer AD.

Cancer Med. 2016 Nov;5(11):3031-3040. doi: 10.1002/cam4.845. Epub 2016 Oct 13.

14.

Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) - a single center analysis.

Deotare U, Shaheen M, Brandwein JM, Pitcher B, Kamel-Reid S, Yee KWL, Schimmer A, Minden MD, Gupta V, Schuh AC.

Hematol Oncol. 2017 Dec;35(4):810-813. doi: 10.1002/hon.2341. Epub 2016 Sep 6.

PMID:
27597292
15.

Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemia.

Sibai H, Seki JT, Wang TQ, Sakurai N, Atenafu EG, Yee KW, Schuh AC, Gupta V, Minden MD, Schimmer AD, Brandwein JM.

Curr Oncol. 2016 Aug;23(4):e355-61. doi: 10.3747/co.23.3077. Epub 2016 Aug 12.

16.

A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.

Yee KW, Chen HW, Hedley DW, Chow S, Brandwein J, Schuh AC, Schimmer AD, Gupta V, Sanfelice D, Johnson T, Le LW, Arnott J, Bray MR, Sidor C, Minden MD.

Invest New Drugs. 2016 Oct;34(5):614-24. doi: 10.1007/s10637-016-0375-2. Epub 2016 Jul 12.

PMID:
27406088
17.

Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study.

Buckstein R, Wells RA, Zhu N, Leitch HA, Nevill TJ, Yee KW, Leber B, Sabloff M, St Hilaire E, Kumar R, Geddes M, Shamy A, Storring J, Kew A, Elemary M, Levitt M, Lenis M, Mamedov A, Zhang L, Rockwood K, Alibhai SM.

Br J Haematol. 2016 Jul;174(1):88-101. doi: 10.1111/bjh.14033. Epub 2016 Mar 15.

PMID:
26991631
18.

A phase I study of elesclomol sodium in patients with acute myeloid leukemia.

Hedley D, Shamas-Din A, Chow S, Sanfelice D, Schuh AC, Brandwein JM, Seftel MD, Gupta V, Yee KW, Schimmer AD.

Leuk Lymphoma. 2016 Oct;57(10):2437-40. doi: 10.3109/10428194.2016.1138293. Epub 2016 Feb 5. No abstract available.

PMID:
26732437
19.

Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-Color flow cytometry diagnosis and HyperCVAD therapy.

Deotare U, Yee KW, Le LW, Porwit A, Tierens A, Musani R, Barth D, Torlakovic E, Schimmer A, Schuh AC, Seftel M, Minden MD, Gupta V, Hyjek E.

Am J Hematol. 2016 Mar;91(3):283-6. doi: 10.1002/ajh.24258. Epub 2016 Jan 11.

20.

Tolerability of Vidaza (azacitidine) subcutaneous administration using a maximum volume of 3 ml per injection.

Ferruccio LF, Murray C, Yee KW, Incekol D, Lee R, Paisley E, Ng P.

J Oncol Pharm Pract. 2016 Aug;22(4):605-10. doi: 10.1177/1078155215598854. Epub 2015 Aug 5.

PMID:
26248754
21.

A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.

How J, Minden MD, Brian L, Chen EX, Brandwein J, Schuh AC, Schimmer AD, Gupta V, Webster S, Degelder T, Haines P, Stayner LA, McGill S, Wang L, Piekarz R, Wong T, Siu LL, Espinoza-Delgado I, Holleran JL, Egorin MJ, Yee KW.

Leuk Lymphoma. 2015;56(10):2793-802. doi: 10.3109/10428194.2015.1018248. Epub 2015 Mar 30.

22.

A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.

Odenike O, Halpern A, Godley LA, Madzo J, Karrison T, Green M, Fulton N, Mattison RJ, Yee KW, Bennett M, Koval G, Malnassy G, Larson RA, Ratain MJ, Stock W.

Invest New Drugs. 2015 Apr;33(2):371-9. doi: 10.1007/s10637-014-0194-2. Epub 2014 Dec 9.

23.

A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukaemia presenting with hyperleucocytosis.

Kuo KH, Callum JL, Panzarella T, Jacks LM, Brandwein J, Crump M, Curtis JE, Gupta V, Lipton JH, Minden MD, Sher GD, Schimmer AD, Schuh AC, Yee KW, Keating A, Messner HA.

Br J Haematol. 2015 Feb;168(3):384-94. doi: 10.1111/bjh.13146. Epub 2014 Oct 10.

PMID:
25303497
24.

Salvage induction chemotherapy after azacitdine treatment failure in patients who received azacitidine as a bridge to allogeneic stem cell transplantation.

Yee KW, Brandwein J, Schimmer AD, Gupta V, Del Bel R, Xu W, Minden MD, Schuh AC.

Br J Haematol. 2014 Jul;166(2):303-6. doi: 10.1111/bjh.12844. Epub 2014 Mar 21. No abstract available.

PMID:
24650042
25.

Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia.

Yee KW, Storring JM, Buckstein R, Wells RA, Xenocostas A, Kovacs MJ, Howson-Jan K, Wang ES, Battista K, Wang L, Oza AM, Ivy SP, Schuh AC.

Leuk Lymphoma. 2014 Nov;55(11):2669-71. doi: 10.3109/10428194.2014.900763. Epub 2014 Apr 22. No abstract available.

PMID:
24611649
26.

Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.

Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, Kennedy JA, Schimmer AD, Schuh AC, Yee KW, McLeod JL, Doedens M, Medeiros JJ, Marke R, Kim HJ, Lee K, McPherson JD, Hudson TJ; HALT Pan-Leukemia Gene Panel Consortium, Brown AM, Yousif F, Trinh QM, Stein LD, Minden MD, Wang JC, Dick JE.

Nature. 2014 Feb 20;506(7488):328-33. doi: 10.1038/nature13038. Epub 2014 Feb 12. Erratum in: Nature. 2014 Apr 17;508(7496):420. Yousif, Fouad [added].

27.

Predictors of outcome in adults with BCR-ABL negative acute lymphoblastic leukemia treated with a pediatric-based regimen.

Brandwein JM, Atenafu EG, Schuh AC, Yee KW, Schimmer AD, Gupta V, Minden MD.

Leuk Res. 2014 May;38(5):532-6. doi: 10.1016/j.leukres.2013.10.025. Epub 2013 Nov 5.

PMID:
24444868
28.

Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies.

Minden MD, Hogge DE, Weir SJ, Kasper J, Webster DA, Patton L, Jitkova Y, Hurren R, Gronda M, Goard CA, Rajewski LG, Haslam JL, Heppert KE, Schorno K, Chang H, Brandwein JM, Gupta V, Schuh AC, Trudel S, Yee KW, Reed GA, Schimmer AD.

Am J Hematol. 2014 Apr;89(4):363-8. doi: 10.1002/ajh.23640. Epub 2014 Mar 3.

29.

Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol.

Martell MP, Atenafu EG, Minden MD, Schuh AC, Yee KW, Schimmer AD, Gupta V, Brandwein JM.

Br J Haematol. 2013 Nov;163(4):458-64. doi: 10.1111/bjh.12561. Epub 2013 Sep 13.

PMID:
24033272
30.

The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics.

How J, Sykes J, Minden MD, Gupta V, Yee KW, Schimmer AD, Schuh AC, Kamel-Reid S, Brandwein JM.

Blood Cancer J. 2013 May 24;3:e116. doi: 10.1038/bcj.2013.14.

31.

Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms.

Kennedy JA, Atenafu EG, Messner HA, Craddock KJ, Brandwein JM, Lipton JH, Minden MD, Schimmer AD, Schuh AC, Yee KW, Gupta V.

Blood. 2013 Apr 4;121(14):2725-33. doi: 10.1182/blood-2012-10-464248. Epub 2013 Jan 29.

32.

High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission.

Hassanein M, Atenafu EG, Schuh AC, Yee KW, Minden MD, Schimmer AD, Gupta V, Brandwein JM.

Leuk Res. 2013 May;37(5):556-60. doi: 10.1016/j.leukres.2013.01.001. Epub 2013 Jan 26.

PMID:
23357460
33.

Outcomes of adult patients with relapsed acute lymphoblastic leukemia following frontline treatment with a pediatric regimen.

Liew E, Atenafu EG, Schimmer AD, Yee KW, Schuh AC, Minden MD, Gupta V, Brandwein JM.

Leuk Res. 2012 Dec;36(12):1517-20. doi: 10.1016/j.leukres.2012.08.019. Epub 2012 Aug 30.

PMID:
22940259
34.

Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia.

How J, Sykes J, Gupta V, Yee KW, Schimmer AD, Schuh AC, Minden MD, Kamel-Reid S, Brandwein JM.

Cancer. 2012 Dec 15;118(24):6110-7. doi: 10.1002/cncr.27683. Epub 2012 Jun 26.

35.

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol.

Thyagu S, Minden MD, Gupta V, Yee KW, Schimmer AD, Schuh AC, Lipton JH, Messner HA, Xu W, Brandwein JM.

Br J Haematol. 2012 Aug;158(4):506-14. doi: 10.1111/j.1365-2141.2012.09182.x. Epub 2012 Jun 1.

PMID:
22650180
36.

Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia.

Saini L, Minden MD, Schuh AC, Yee KW, Schimmer AD, Gupta V, Atenafu EG, Murray C, Nixon S, Brandwein JM.

Am J Hematol. 2012 Mar;87(3):323-6. doi: 10.1002/ajh.22268. Epub 2011 Dec 27.

37.

A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response.

Brandwein JM, Hedley DW, Chow S, Schimmer AD, Yee KW, Schuh AC, Gupta V, Xu W, Kamel-Reid S, Minden MD.

Leukemia. 2011 Jun;25(6):945-52. doi: 10.1038/leu.2011.34. Epub 2011 Mar 15.

PMID:
21403650
38.

Older patients with acute myeloid leukemia.

Yee KW, Keating A.

Expert Rev Hematol. 2010 Dec;3(6):755-74. doi: 10.1586/ehm.10.68. Review.

PMID:
21091151
39.

Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia.

Al-Khabori M, Minden MD, Yee KW, Gupta V, Schimmer AD, Schuh AC, Xu W, Brandwein JM.

Leuk Lymphoma. 2010 Jan;51(1):61-5. doi: 10.3109/10428190903388376.

PMID:
20017600
40.

The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin.

Schittenhelm MM, Kampa KM, Yee KW, Heinrich MC.

Cell Cycle. 2009 Aug 15;8(16):2621-30. Epub 2009 Aug 24.

PMID:
19625780
41.

Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen.

Storring JM, Minden MD, Kao S, Gupta V, Schuh AC, Schimmer AD, Yee KW, Kamel-Reid S, Chang H, Lipton JH, Messner HA, Xu W, Brandwein JM.

Br J Haematol. 2009 Jun;146(1):76-85. doi: 10.1111/j.1365-2141.2009.07712.x. Epub 2009 May 4.

PMID:
19438471
42.

A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over.

Brandwein JM, Leber BF, Howson-Jan K, Schimmer AD, Schuh AC, Gupta V, Yee KW, Wright J, Moore M, MacAlpine K, Minden MD; NCI CTEP Protocol 6670.

Leukemia. 2009 Apr;23(4):631-4. doi: 10.1038/leu.2008.341. Epub 2008 Dec 18.

PMID:
19092853
43.

Acute promyelocytic leukemia in patients aged 70 years and over -- a single center experience of unselected patients.

Disperati P, Minden MD, Gupta V, Schimmer AD, Schuh AC, Yee KW, Kamel-Reid S, Chang H, Xu W, Brandwein JM.

Leuk Lymphoma. 2007 Aug;48(8):1654-8. No abstract available.

PMID:
17701604
44.

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

Zeng Z, Sarbassov dos D, Samudio IJ, Yee KW, Munsell MF, Ellen Jackson C, Giles FJ, Sabatini DM, Andreeff M, Konopleva M.

Blood. 2007 Apr 15;109(8):3509-12. Epub 2006 Dec 19.

45.

FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).

Schittenhelm MM, Yee KW, Tyner JW, McGreevey L, Haley AD, Town A, Griffith DJ, Bainbridge T, Braziel RM, O'Farrell AM, Cherrington JM, Heinrich MC.

Leukemia. 2006 Nov;20(11):2008-14. Epub 2006 Sep 14.

PMID:
16990784
46.

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.

Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M, Giles FJ.

Clin Cancer Res. 2006 Sep 1;12(17):5165-73.

47.

Chronic lymphocytic leukemia: diagnosis and treatment.

Yee KW, O'Brien SM.

Mayo Clin Proc. 2006 Aug;81(8):1105-29. Review.

PMID:
16901035
48.

Cutaneous leukocytoclastic vasculitis in a patient with myelodysplastic syndrome after therapy with the rapamycin analogue everolimus: case report and review of the literature.

Yee KW, Hymes SR, Heller L, Prieto VG, Welch MA, Giles FJ.

Leuk Lymphoma. 2006 May;47(5):926-9. No abstract available.

PMID:
16753882
49.

Emerging drugs for chronic lymphocytic leukaemia.

Yee KW, O'Brien SM.

Expert Opin Emerg Drugs. 2006 Mar;11(1):167-89. Review.

PMID:
16503834
50.

Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.

Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'brien SM, Jeha S, Andreeff M, Cahill A, Sznol M, Giles FJ.

Leuk Res. 2006 Jul;30(7):813-22. Epub 2006 Feb 14.

PMID:
16478631

Supplemental Content

Support Center